

Supplement Table 1. Demographic characteristics and past medical history of the study population

Variable	Total (n=122)	ADT+abiraterone (n=102)	ADT+docetaxel (n=20)	p-value
Age (y)	68.9±8.3	69.5±8.3	65.8±7.8	0.065
BMI (kg/m ²)	23.9±2.9	23.8±3.0	24.7±2.4	0.199
ECOG PS				0.777
0	94 (77.0)	79 (77.5)	15 (75.0)	
≥1	28 (23.0)	23 (22.5)	5 (25.0)	
DM	23 (18.9)	18 (17.6)	5 (25.0)	0.684
Hypertension	58 (47.5)	44 (43.1)	14 (70.0)	0.086
CCI score				0.111
0–1	101 (82.8)	87 (85.3)	14 (70.0)	
≥2	21 (17.2)	15 (14.7)	6 (30.0)	
Smoking				0.744
Nonsmoker	35 (28.7)	29 (28.4)	6 (30.0)	
Ex smoker	46 (38.7)	38 (37.3)	8 (40.0)	
Current smoker	15 (12.3)	14 (13.7)	1 (5.0)	
Unknown	26 (21.3)	21 (20.6)	5 (25.0)	

Values are presented as means±standard deviations, medians (interquartile ranges), or numbers (%), unless otherwise indicated.

ADT: androgen-deprivation therapy, BMI: body mass index, CCI: Charlson Comorbidity Index, DM: diabetes mellitus, ECOG PS: Eastern Cooperative Oncology Group performance status.